BRAF and neoplasm: Currently, multiple diagnostic methodologies are used to detect the presence of BRAF mutations in tumor tissue, including high-resolution melt polymerase chain reaction (PCR); the Cobas 4800 BRAF V600 mutation test (Roche Diagnostics, Indianapolis, IN, USA); real-time allele-specific amplification PCR; next-generation sequencing; digital droplet PCR; immunohistochemistry, which is restricted to the BRAFV600E mutation; and Idylla, an automated, PCR-based, molecular platform (Biocartis, Jersey City, NJ, USA) [1,11,13,14,15].